Genomes and Genes
lewy body disease
Summary: A neurodegenerative disease characterized by dementia, mild parkinsonism, and fluctuations in attention and alertness. The neuropsychiatric manifestations tend to precede the onset of bradykinesia, MUSCLE RIGIDITY, and other extrapyramidal signs. DELUSIONS and visual HALLUCINATIONS are relatively frequent in this condition. Histologic examination reveals LEWY BODIES in the CEREBRAL CORTEX and BRAIN STEM. SENILE PLAQUES and other pathologic features characteristic of ALZHEIMER DISEASE may also be present. (From Neurology 1997;48:376-380; Neurology 1996;47:1113-1124)
Publications276 found, 100 shown here
- Cortical Lewy body pathology in the diagnosis of dementiaA J Harding
Prince of Wales Medical Research Institute, Sydney, NSW, Australia
Acta Neuropathol 102:355-63. 2001..These results suggest that dual pathologies cause DLB, and high densities of parahippocampal Lewy bodies indicate dementia regardless of additional pathologies...
- Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodiesMichael L Kramer
Prion and Dementia Research Unit, Institute of Neuropathology, University of Goettingen, 37075 Goettingen, Germany
J Neurosci 27:1405-10. 2007..This concept may also be valid for Parkinson's disease...
- Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological studyJennifer Molano
Mayo Clinic, Rochester, MN 55905, USA
Brain 133:540-56. 2010There are little data on the relationship between Lewy body disease and mild cognitive impairment syndromes...
- Diagnosis and management of dementia with Lewy bodies: third report of the DLB ConsortiumI G McKeith
Institute for Ageing and Health, University of Newcastle upon Tyne, UK
Neurology 65:1863-72. 2005....
- Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body diseaseJohn P Anderson
Elan Pharmaceuticals, South San Francisco, California 94080, USA
J Biol Chem 281:29739-52. 2006....
- Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brainsKazuhiro Imamura
Department of Neurology, Okazaki City Hospital, 3 1 Goshoai, Kouryuuji cho, 444 8553, Okazaki, Aichi, Japan
Acta Neuropathol 109:141-50. 2005....
- Axonopathy in an Î±-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated Î±-synucleinDora Games
Neotope Biosciences, South San Francisco, California, USA
Am J Pathol 182:940-53. 2013..These results show that neuritic dystrophy is a prominent pathologic feature of the mThy1-Î±-syn tg model and suggest that CT Î±-syn might play an important role in the process of axonal damage in these mice as well as in DLB and PD...
- Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathyLeslie Crews
Department of Pathology, University of California San Diego, La Jolla, California, United States of America
PLoS ONE 5:e9313. 2010b>Lewy body disease is a heterogeneous group of neurodegenerative disorders characterized by alpha-synuclein accumulation that includes dementia with Lewy bodies (DLB) and Parkinson's Disease (PD)...
- Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseasesBrian Spencer
Department of Neurosciences, University of California, San Diego, La Jolla, California 92093 0624, USA
J Neurosci 29:13578-88. 2009..Accumulation of the synaptic protein alpha-synuclein (alpha-syn) is a hallmark of Parkinson's disease (PD) and Lewy body disease (LBD), a heterogeneous group of disorders with dementia and parkinsonism, where Alzheimer's disease and PD ..
- DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkersC F Lippa
Department of Neurology, Drexel University College of Medicine, Philadelphia, PA 19102, USA
Neurology 68:812-9. 2007....
- Visual perception in Parkinson disease dementia and dementia with Lewy bodiesU P Mosimann
Institute for Ageing and Health, Wolfson Research Centre, Newcastle General Hospital, Newcastle upon Tyne NE4 6BE, UK
Neurology 63:2091-6. 2004..To quantify visual discrimination, space-motion, and object-form perception in patients with Parkinson disease dementia (PDD), dementia with Lewy bodies (DLB), and Alzheimer disease (AD)...
- α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort studyBrit Mollenhauer
Paracelsus Elena Klinik, Kassel, Germany
Lancet Neurol 10:230-40. 2011..We aimed to assess whether reduction of α-synuclein concentrations in CSF was a marker for α-synuclein deposition in the brain, and therefore diagnostic of synucleinopathies...
- Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disordersPetra E Spies
Department of Geriatric Medicine, Radboud University Nijmegen Medical Centre, Donders Centre for Neuroscience, Nijmegen, The Netherlands
J Alzheimers Dis 16:363-9. 2009..We conclude that in clinically diagnosed patients, alpha-synuclein does not appear to be a useful biomarker for the differentiation between DLB and other types of dementia...
- Lrrk2 interaction with alpha-synuclein in diffuse Lewy body diseaseHong Qing
Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z3
Biochem Biophys Res Commun 390:1229-34. 2009..are the leading cause of genetically inherited Parkinson's disease (PD) and its more severe variant diffuse Lewy body disease (DLB). Pathological mutations in Lrrk2 are autosomal dominant, suggesting a gain of function...
- Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body diseaseEliezer Masliah
Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America
PLoS ONE 6:e19338. 2011..These results suggest that passive immunization with monoclonal antibodies against the CT of α-syn may be of therapeutic relevance in patients with PD and DLB...
- Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunctionThomas G Beach
Sun Health Research Institute, Sun City, AZ 85351, USA
Acta Neuropathol 117:613-34. 2009..autopsied subjects included elderly subjects with Parkinson's disease, dementia with Lewy bodies, incidental Lewy body disease and Alzheimer's disease with Lewy bodies, as well as comparison groups without Lewy bodies...
- Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promotersEdward Rockenstein
Department of Neurosciences, University of California San Diego, La Jolla, California 92093 0624, USA
J Neurosci Res 68:568-78. 2002Accumulation of alpha-synuclein has been associated with neurodegenerative disorders, such as Lewy body disease and multiple system atrophy...
- Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?Annika Ohrfelt
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
Neurosci Lett 450:332-5. 2009..The lower alpha-syn levels in AD, as well as the association of alpha-syn reduction with AD severity, approximated by MMSE, suggests that it may be a general marker of synapse loss, a hypothesis that warrants further investigation...
- A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body diseaseH L Melrose
Molecular Genetics Laboratory and Core, Morris K Udall Parkinson s Disease Research Center of Excellence, Mayo Clinic, Department of Neuroscience, 4500 San Pablo Road, Jacksonville, FL 32224, USA
Neuroscience 147:1047-58. 2007..from wild type and human Lrrk2 transgenic bacterial artificial chromosome (BAC) mice, and from diffuse Lewy body disease (DLBD) patients...
- Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobeA J Harding
Prince of Wales Medical Research Institute and University of New South Wales, Barker Street, Sydney, NSW 2031, Australia
Brain 125:391-403. 2002..Thus, our results suggest that the distribution of temporal lobe LB is more related to the presence and duration of visual hallucinations in cases with LB than to the presence, severity or duration of dementia...
- Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synucleinJ E Galvin
Department of Neurology, Medical College of Pennsylvania, Hahnemann University, 245 North 15th Street, Philadelphia, PA 19129, USA
Proc Natl Acad Sci U S A 96:13450-5. 1999..Our findings broaden the concept of neurodegenerative "synucleinopathies" by implicating betaS and gammaS, in addition to alphaS, in the onset/progression of PD and DLB...
- Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body diseaseKenya Nishioka
Department of Neuroscience, Mayo Clinic Florida, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
Arch Neurol 67:970-5. 2010To determine the association of the genes that encode alpha-, beta-, and gamma-synuclein (SNCA, SNCB, and SNCG, respectively) with diffuse Lewy body disease (DLBD).
- GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathologyDebby Tsuang
Veterans Affairs Puget Sound Health Care System Seattle, WA, USA
Neurology 79:1944-50. 2012..Parkinson disease (PD) and are a well-established susceptibility factor for PD, which is characterized by Lewy body disease (LBD) neuropathologic changes (LBDNCs)...
- Causal relation between alpha-synuclein gene duplication and familial Parkinson's diseaseP Ibanez
INSERM U289, Neurologie et Thérapeutique Expérimentale, Hopital de la Pitie Salpetriere, AP HP, Paris, France
Lancet 364:1169-71. 2004..These results indicate that SNCA is more frequently associated with familial Parkinson's disease than previously thought, and that there is a clear dosage effect according to the number of supernumerary copies of this gene...
- Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodiesKejal Kantarci
Departments of Radiology, Mayo Clinic, Rochester, MN, USA
Neurology 79:553-60. 2012..To determine the association between the focal atrophy measures on antemortem MRI and postmortem neuropathologic classification of dementia with Lewy bodies (DLB) using the Third Report of the DLB Consortium criteria...
- Differences in neuropathologic characteristics across the Lewy body dementia spectrumC Ballard
Wolfson Centre for Age Related Diseases, Wolfson Building, Guy s Campus, King s College London, London, SE1 1UL, UK
Neurology 67:1931-4. 2006....
- Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disordersThomas G Beach
Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
Acta Neuropathol 119:689-702. 2010..tissue from 41 different sites in the bodies of 92 subjects, including 23 normal elderly, 7 with incidental Lewy body disease (ILBD), 17 with Parkinson's disease (PD), 9 with dementia with Lewy bodies (DLB), 19 with Alzheimer's ..
- Prevalence and impact of vascular and Alzheimer pathologies in Lewy body diseaseKurt A Jellinger
Institute of Clinical Neurobiology, Vienna, Austria
Acta Neuropathol 115:427-36. 2008....
- What best differentiates Lewy body from Alzheimer's disease in early-stage dementia?Pietro Tiraboschi
Dipartimento di Scienze Neurologiche, Ospedale Niguarda Ca Granda, Milano, Italy
Brain 129:729-35. 2006..This suggests that clinical history plus a brief assessment of visuospatial function may be of the greatest value in correctly identifying DLB early during the course of disease...
- Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre studyIan McKeith
Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, UK
Lancet Neurol 6:305-13. 2007..Diagnostic accuracy, positive and negative predictive values, and inter-reader agreement were the secondary endpoints and a subgroup of possible DLB patients was also included...
- Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathyMalin Wennström
Lund University, Department of Clinical Sciences Malmo, Molecular Memory Research Unit, The Wallenberg Laboratory at Skåne University Hospital, Malmo, Sweden
PLoS ONE 8:e53250. 2013....
- Change in perfusion, hallucinations and fluctuations in consciousness in dementia with Lewy bodiesJohn T O'Brien
Institute for Ageing and Health, University of Newcastle upon Tyne, Wolfson Research Centre, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne, NE4 6BE, UK
Psychiatry Res 139:79-88. 2005..We have identified important neural correlates of key clinical features in Lewy body dementia and postulate that the associations can be understood through the influence of the cholinergic system on attention...
- Neuropathology of Lewy body disordersEniko Kovari
Department of Psychiatry, HUG Belle Idée, University Hospitals of Geneva, Switzerland
Brain Res Bull 80:203-10. 2009..The recent progress of neuropathology in this field made it possible to define clinical and neuropathological guidelines for the diagnosis. This review briefly describes the most important data of all Lewy body related disorders...
- Differences in clinical course between dementia with Lewy bodies and Alzheimer's diseaseH Hanyu
Department of Geriatric Medicine, Tokyo Medical University, Tokyo, Japan
Eur J Neurol 16:212-7. 2009..To investigate whether there may be differences in the clinical course and changes in cognitive progression between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD)...
- Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid-β pathwayWalter Maetzler
Center of Neurology, Department of Neurodegeneration and Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany
J Alzheimers Dis 27:119-26. 2011..Taken together, our results provide first evidence for disease-relevant but potentially distinct roles of UA in the blood and CSF compartment, respectively, in LBD...
- MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementiaR Barber
Institute for the Health of the Elderly, Newcastle General Hospital, Newcastle upon Tyne, UK
Neurology 54:1304-9. 2000..To compare global and regional atrophy on MRI in subjects with dementia with Lewy bodies (DLB), AD, vascular dementia (VaD), and normal aging. In addition, the relationship between APOE-epsilon4 genotype and volumetric indices was examined...
- The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body diseaseWalter Maetzler
Department of Neurodegeneration, University of Tuebingen, Germany
J Alzheimers Dis 19:937-42. 2010A large proportion of demented Lewy body disease patients have Alzheimer's disease (AD)- like pathology, in particular amyloid-beta (Abeta) plaques...
- Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer diseaseC Ballard
Institute for the Health of the Elderly, Wolfson Research Centre, Newcastle General Hospital, Westgate Road, Newcastle, England NE4 6BE
Arch Neurol 58:977-82. 2001....
- Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body diseaseSatoshi Orimo
Department of Neurology, Kanto Central Hospital, 6 25 1 Kami Yoga, Setagaya Ku, 158 8531, Tokyo, Japan
Acta Neuropathol 109:583-8. 2005..To elucidate the extent, frequency and pattern of cardiac sympathetic nerve involvement in Lewy body disease and related neurodegenerative disorders, we immunohistochemically examined heart tissues from patients with ..
- Incidental Lewy body disease: clinical comparison to a control cohortCharles H Adler
Parkinson s Disease and Movement Disorders Center, Mayo Clinic, Scottsdale, Arizona 85259, USA
Mov Disord 25:642-6. 2010Limited clinical information has been published on cases pathologically diagnosed with incidental Lewy body disease (ILBD)...
- Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disordersE Masliah
Department of Neurosciences, Department of Pathology, University of California San Diego, La Jolla, CA 92093 0624, USA
Science 287:1265-9. 2000..These results suggest that accumulation of wild-type alpha-synuclein may play a causal role in Parkinson's disease and related conditions...
- CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's diseaseMoeko Noguchi-Shinohara
Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
Brain Res 1251:1-6. 2009..However, the lower alpha-synuclein levels in DLB patients with longer duration suggest a reduction in CSF alpha-synuclein in association with increased severity of alpha-synucleinopathy in the brain...
- Beta-synuclein gene alterations in dementia with Lewy bodiesH Ohtake
Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan
Neurology 63:805-11. 2004..To determine whether mutations in the genes for alpha-synuclein or beta-synuclein are responsible for dementia with Lewy bodies (DLB), a disorder closely related to Parkinson disease (PD)...
- S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective functionKenny K K Chung
Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Science 304:1328-31. 2004..in vitro, as well as in vivo in a mouse model of PD and in brains of patients with PD and diffuse Lewy body disease. Moreover, S-nitrosylation inhibits parkin's ubiquitin E3 ligase activity and its protective function...
- Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilizationDaryl A Bosco
Department of Chemistry and The Skaggs Institute of Chemical Biology, The Scripps Research Institute, 10550 N Torrey Pines Road, La Jolla, California 92037, USA
Nat Chem Biol 2:249-53. 2006..By extension, these data lead to the hypothesis that oxidative stress produces cholesterol aldehydes that enable alpha-synuclein aggregation, leading to a pathologic cycle...
- A clinico-pathological study of subtypes in Parkinson's diseaseM Selikhova
Queen Square Brain Bank for Neurological Disorders and Institute of Neurology, University College, London, UK
Brain 132:2947-57. 2009..047). An analysis of cases with pathologically defined neocortical Lewy body disease confirmed the link between bradykinetic onset, cognitive decline and Lewy body deposition in the neocortex...
- EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-upLaura Bonanni
Department of Neurology, Aging Research Center, Ce S I, Gabriele D Annunzio University Foundation, University G d Annunzio of Chieti Pescara, via Fonte Romana, 65124 Pescara, Italy
Brain 131:690-705. 2008....
- Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy studyDavid R Williams
Queen Square Brain Bank for Neurological Disorders and Institute of Neurology, University College London, London, UK
Lancet Neurol 4:605-10. 2005..The cause of VH is now thought to be nerve-cell loss and Lewy-body pathology in the ventral-temporal regions of the brain. However, the use of VH as a clinical sign of PD has not been investigated...
- Mapping of brain acetylcholinesterase alterations in Lewy body disease by PETH Shimada
Molecular Neuroimaging Group, Molecular Imaging Center, National Institute of Radiological Sciences, 4 9 1 Anagawa, Inage Ku, Chiba shi, Chiba 260 8555, Japan
Neurology 73:273-8. 2009..To characterize brain cholinergic deficits in Parkinson disease (PD), PD with dementia (PDD), and dementia with Lewy bodies (DLB)...
- A critical reappraisal of current staging of Lewy-related pathology in human brainKurt A Jellinger
Institute of Clinical Neurobiology, Kenyongasse 18, 1070, Vienna, Austria
Acta Neuropathol 116:1-16. 2008....
- Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body diseaseJose Bras
Molecular Genetics Unit, National Institutes on Aging, Bethesda, MD, USA
FEBS J 275:5767-73. 2008..mutations at the glucosecerebrosidase locus have recently been shown to be a potent risk factor for Lewy body disease. Based on this observation, we have re-evaluated the likelihood that the different PARK loci (defined using ..
- Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's diseaseDennis W Dickson
Neuropathology Laboratory, Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
Acta Neuropathol 115:437-44. 2008..When Lewy bodies are found in normal individuals, the process is sometimes referred to as incidental Lewy body disease (iLBD)...
- Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosisE J Burton
Wolfson Research Centre, Institute for Ageing and Health, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, UK
Brain 132:195-203. 2009..Pathologically, it is more strongly related to tangle rather than plaque or Lewy body pathology in the temporal lobe. It may have utility as a means for stratifying samples in vivo on the basis of putative differences in pathology...
- Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodiesKaterina E Paleologou
Division of Biomedical and Life Sciences, School of Health and Medicine, Lancaster University, Lancaster LA1 4YQ, UK
Brain 132:1093-101. 2009..Furthermore, these findings establish FILA-1 as a very sensitive tool for the detection of oligomeric forms of alpha-syn in human brain lysates...
- Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity?Dag Aarsland
Psychiatric Clinic, Rogaland Central Hospital, PO Box 1163, Hillevaag, 4095 Stavanger, Norway
J Geriatr Psychiatry Neurol 17:137-45. 2004....
- Why people see things that are not there: a novel Perception and Attention Deficit model for recurrent complex visual hallucinationsDaniel Collerton
South of Tyne and Wearside Mental Health NHS Trust, Bensham Hospital, Gateshead NE8 4YL, United Kingdom
Behav Brain Sci 28:737-57; discussion 757-94. 2005..Several tests of the model are indicated, together with a number of treatment options that it generates...
- A comparison of (99m)Tc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mappingSean J Colloby
Wolfson Research Centre, The Institute for Ageing and Health, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne, NE4 6BE, UK
Eur J Nucl Med Mol Imaging 29:615-22. 2002..In conclusion, we found evidence of frontal and parietal hypoperfusion in both AD and DLB, while temporal perfusion deficits were observed exclusively in AD and parieto-occipital deficits in DLB...
- Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trialDag Aarsland
The Norwegian Centre for Movement Disorders, Stavanger University Hospital, 4068 Stavanger, Norway
Lancet Neurol 8:613-8. 2009..We aimed to test the safety and efficacy of the N-methyl D-aspartate (NMDA) receptor antagonist memantine in patients with PDD or DLB...
- CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's diseaseFransje E Reesink
Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands
J Alzheimers Dis 22:87-95. 2010..05). Ultimately, CSF α-synuclein was not a useful diagnostic biomarker to differentiate DLB and/or PD (α-synucleinopathies) from AD or SC. In DLB patients maybe lower CSF α-synuclein levels are related to worse cognitive performance...
- Visual hallucinations in dementia with Lewy bodies: transcranial magnetic stimulation studyJohn Paul Taylor
Institute for Ageing and Health, Newcastle University, Wolfson Research Centre, Campus for Ageing and Vitality, Newcastle upon Tyne NE4 5PL, UK
Br J Psychiatry 199:492-500. 2011..The aetiology of visual hallucinations is poorly understood in dementia with Lewy bodies. Pathological alterations in visual cortical excitability may be one contributory mechanism...
- Thalamic D2 receptors in dementia with Lewy bodies, Parkinson's disease, and Parkinson's disease dementiaMargaret A Piggott
IAH Research Laboratories, Institute for Ageing and Health, University of Newcastle upon Tyne, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne, UK
Int J Neuropsychopharmacol 10:231-44. 2007..D2 receptor binding did not vary with cognitive decline (MMSE) or visual hallucinations, but was significantly higher with increased extrapyramidal symptoms...
- Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body diseaseKatrin Beyer
Department of Pathology, Hospital Germans Trias i Pujol, Autonomous University of Barcelona, Barcelona, Spain
Neurogenetics 9:163-72. 2008..In conclusion, isoform-expression profiles in LB diseases represent additional evidence for the direct involvement of isoform-expression deregulation in the development of neurodegenerative disorders...
- Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trialMurat Emre
Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Lancet Neurol 9:969-77. 2010..Therefore, the efficacy and safety of memantine were investigated in patients with mild to moderate Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB)...
- CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDDAlessandro Stefani
Dipartimento di Neuroscienze, Universita di Roma Tor Vergata, Rome, Italy
J Neural Transm 119:861-75. 2012..However, more complete data, possibly collected in fieri during the progressive derangement of cognitive abilities, are needed to improve our ability to decipher and treat these entities...
- Levodopa response in dementia with lewy bodies: a 1-year follow-up studyClaudio Lucetti
Neurology Unit, Hospital of Viareggio, Italy
Parkinsonism Relat Disord 16:522-6. 2010..To evaluate levodopa responsiveness in patients with probable dementia with Lewy bodies (DLB) compared to early Parkinson's disease (PD) patients...
- Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometryE J Burton
Institute for Ageing and Health, University of Newcastle upon Tyne, United Kingdom
Neuroimage 17:618-30. 2002..Comparison of dementia groups showed preservation of the medial temporal lobe, hippocampus, and amygdala in DLB relative to AD. Significant gray matter loss was also observed in the thalamus of AD patients compared to DLB...
- Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer diseaseJ E Galvin
Center of Excellence on Brain Aging, New York University Langone School of Medicine, 145 East 32nd St, Second Floor, New York, NY 10016, USA
Neurology 76:1797-803. 2011..We performed resting state blood oxygen level-dependent (BOLD) functional connectivity MRI (fcMRI) to determine whether there were differences between AD and DLB...
- Glucocerebrosidase mutations alter the endoplasmic reticulum and lysosomes in Lewy body diseaseMarzena Kurzawa-Akanbi
Medical Toxicology Centre, Wolfson Building, Newcastle University, Newcastle upon Tyne, UK
J Neurochem 123:298-309. 2012b>Lewy body disease (LBD) development is enhanced by mutations in the GBA gene coding for glucocerebrosidase (GCase)...
- Early diagnosis of dementiaK S SantaCruz
University of Kansas Medical Center, Kansas City, USA
Am Fam Physician 63:703-13, 717-8. 2001..Follow-up by the patient's family physician is appropriate in most patients. However, a subspecialist may be helpful in the diagnosis and management of patients with dementia with an unusual presentation or following an atypical course...
- Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in lewy body diseaseYuichi Fumimura
Department of Neuropathology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
J Neuropathol Exp Neurol 66:354-62. 2007b>Lewy body disease is defined as Lewy body-related neuronal degeneration involving the nigrostriatal system, limbic-neocortical system, and peripheral autonomic nervous system (PANS)...
- Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body diseaseMichael T Lin
Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, NY, USA
Ann Neurol 71:850-4. 2012..To address this issue, we studied early stage PD cases and cases of incidental Lewy body disease (ILBD), which is thought to represent presymptomatic PD...
- Enhanced accumulation of phosphorylated alpha-synuclein and elevated beta-amyloid 42/40 ratio caused by expression of the presenilin-1 deltaT440 mutant associated with familial Lewy body disease and variant Alzheimer's diseaseHiroyuki Kaneko
Department of Molecular Neuroscience, Center for Bioresources, Niigata University, Niigata 951 8585, Japan
J Neurosci 27:13092-7. 2007....
- Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disordersOzlem Goker-Alpan
Section on Molecular Neurogenetics, Medical Genetics Branch, NHGRI, National Institutes of Health, Bethesda, MD 20892 3708, USA
Acta Neuropathol 120:641-9. 2010..Unraveling the role of mutant glucocerebrosidase in the development of this pathology will further our understanding of the lysosomal pathways that likely contribute to the formation and/or clearance of these protein aggregates...
- Coexistent Lewy body disease in a case of "visual variant of Alzheimer's disease"D F Tang-Wai
J Neurol Neurosurg Psychiatry 74:389. 2003
- The characterisation and impact of 'fluctuating' cognition in dementia with Lewy bodies and Alzheimer's diseaseC Ballard
Institute of Health for the Elderly, Newcastle General Hospital, Newcastle upon Tyne, UK
Int J Geriatr Psychiatry 16:494-8. 2001..CONCLUSIONS: Although attention is the cognitive domain which fluctuates most markedly, other cognitive domains are also affected. FC also has a significant independent impact on activities of daily living...
- Rapidly progressive diffuse Lewy body diseaseCarles Gaig
Neurology Service, Hospital Clinic of Barcelona, Barcelona, Spain
Mov Disord 26:1316-23. 2011..Lewy body syndromes (mainly Parkinson's disease and dementia with Lewy bodies) share many clinical features and usually have a slowly progressive course. Some patients may show rapid symptoms progression...
- The influence of vascular risk factors on the survival rate of patients with dementia with Lewy bodies and Alzheimer diseaseRadosław Magierski
Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Lodz, Poland
Neurol Neurochir Pol 44:139-47. 2010..The aim of this study was to determine whether dementia with Lewy bodies (DLB) progres-ses more rapidly than Alzheimer disease (AD) and to compare survival after dementia onset and mortality in both dementia groups...
- Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label studySatoru Mori
Department of Neurology, Matsushita Memorial Hospital, Moriguchi, Osaka, Japan
Psychiatry Clin Neurosci 60:190-5. 2006....
- Autonomic dysfunction in dementia with Lewy bodiesP Thaisetthawatkul
Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
Neurology 62:1804-9. 2004..To assess autonomic function in patients with dementia with Lewy bodies (DLB)...
- The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutationsOzlem Goker-Alpan
Section on Molecular Neurogenetics, National Human Genome Research Institute, National Institutes of Health, 35 Convent Dr, MSC 3708, Bldg 35, Room 1A213, Bethesda, MD 20892 3708, USA
Arch Neurol 65:1353-7. 2008..Mutations in the glucocerebrosidase gene (GBA) result in Gaucher disease and can be associated with a phenotype characterized by adult-onset progressive neurologic deterioration and parkinsonism...
- Patients with dementia with lewy bodies have more impaired quality of life than patients with Alzheimer diseaseFredrik Bostrom
Clinical Memory Research Unit, Department of Clinical Sciences, Malmo University Hospital, Lund University, Malmo, Sweden
Alzheimer Dis Assoc Disord 21:150-4. 2007....
- Alteration of autophagosomal proteins (LC3, GABARAP and GATE-16) in Lewy body diseaseKunikazu Tanji
Department of Neuropathology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, 5 Zaifu cho, Hirosaki 036 8562, Japan
Neurobiol Dis 43:690-7. 2011..In this study, we determined whether Atg8 homologues are affected in Lewy body disease, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB)...
- Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease courseNúria Setó-Salvia
Neurology Department Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
Mov Disord 27:393-9. 2012....
- Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodiesMona K Beyer
Department of Radiology, Stavanger University Hospital, Stavanger, Norway
Neurology 69:747-54. 2007..We conducted a study using voxel-based morphometry (VBM) to explore the pattern of cortical atrophy in DLB and PDD...
- Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-β42 levels in Lewy body diseaseWalter Maetzler
Center of Neurology, Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany
J Alzheimers Dis 22:933-8. 2010b>Lewy body disease, defined by the occurrence of α-synuclein aggregates as fibrils in Lewy bodies and Lewy neurites, is associated with increased probabilities for both co-occurrence of dementia, and co-occurrence of Alzheimer's disease (..
- The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's diseaseC Ballard
Reader in Old Age Psychiatry, University of Newcastle, Newcastle General Hospital, Newcastle upon Tyne, UK
Int J Geriatr Psychiatry 16:499-503. 2001..Little is known about the rate of progression or associations of cognitive impairment in dementia with Lewy bodies (DLB), or the associations of accelerated decline...
- Cerebral metabolic dysfunction in patients with dementia with Lewy bodies and visual hallucinationsRobert Perneczky
Department of Psychiatry and Psychotherapy, Technical University Munich, Munich, Germany
Dement Geriatr Cogn Disord 25:531-8. 2008..To identify the pattern of cerebral hypometabolism in patients with dementia with Lewy bodies (DLB) and visual hallucinations (VH)...
- Glucocerebrosidase mutations are an important risk factor for Lewy body disordersO Goker-Alpan
Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD 20892 3708, USA
Neurology 67:908-10. 2006..Mutations in this lysosomal protein may interfere with the clearance or promote aggregation of alpha-synuclein...
- The period of hypotension following orthostatic challenge is prolonged in dementia with Lewy bodiesM Andersson
Neuropsychiatric Clinic, Malmo University Hospital, Malmo, Sweden
Int J Geriatr Psychiatry 23:192-8. 2008....
- Investigation of Lewy pathology in the visual pathway of brains of dementia with Lewy bodiesRyoko Yamamoto
Department of Psychiatry, Juntendo Tokyo Koto Geriatric Medical Center, Juntendo University School of Medicine, 3 3 20 Shinsuna, Koto ku, Tokyo 136 0075, Japan
J Neurol Sci 246:95-101. 2006..In addition, we compared Lewy pathology between cases with and without visual hallucinations, and showed no significant differences between the two groups...
- Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristicsWalter Maetzler
Center of Neurology, Department of Neurodegeneration and Hertie Institute for Clinical Brain Research, University of Tuebingen, Germany
Neurobiol Dis 34:107-12. 2009About one fourth of Lewy body disease (LBD) patients show cortical beta-amyloid load, basically a hallmark of Alzheimer disease (AD)...
- Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicityDiana L Price
Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America
PLoS ONE 5:e14020. 2010..These results highlight the therapeutic importance of mGluR5 antagonists in alpha-synucleinopathies...
- Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not ADK Lobotesis
Institute for the Health of the Elderly, Newcastle General Hospital, Newcastle upon Tyne, UK
Neurology 56:643-9. 2001..Although not diagnostically specific in individual cases, occipital hypoperfusion on SPECT should raise suspicion that DLB may be the cause of dementia, prompting careful search for other features of the disorder...
- Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonismD R Williams
Faculty of Medicine, Neurosciences, Monash University, Alfred Hospital Campus, Commercial Rd, Melbourne 3004, Australia
J Neurol Neurosurg Psychiatry 79:652-5. 2008..To address the issue of diagnosis in patients with parkinsonism, we developed instructions for a structured interview (Queen Square Visual Hallucination Inventory (QSVHI)), capable of rapidly screening for VH in the outpatient setting...
- Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLBT Mori
Department of Neuropsychiatry, Ehime University School of Medicine, Ehime, Japan
Neurology 66:935-7. 2006..Hallucinations attenuated while receiving therapy, whereas occipital rCBF focally increased, suggesting that functional visual association cortex deficits may cause visual hallucinations in patients with DLB...
- Glucocerebrosidase mutations in diffuse Lewy body diseaseKenya Nishioka
Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA
Parkinsonism Relat Disord 17:55-7. 2011..8% (4/59) of cases with a pathological diagnosis of diffuse Lewy body disease. Taken with previous studies, it appears that GBA mutations are associated with a more diffuse pattern of ..
- Value of (99m)Tc-ECD SPET for the diagnosis of dementia with Lewy bodiesJacques Pasquier
Departement de Medecine Nucleaire, Institut Paoli Calmettes, Universite de la Mediterranee, 232 Boulevard Sainte Marguerite, BP 156, 13273 Marseille Cedex 9, France
Eur J Nucl Med Mol Imaging 29:1342-8. 2002..The findings also support a link between visual hallucinations and structural/functional changes in the occipital region in DLB patients...
- Clinical findings, functional abilities and caregiver distress in the early stage of dementia with Lewy bodies (DLB) and Alzheimer's disease (AD)Monica Ricci
Regina Apostolorum Hospital, Albano Laziale, Italy
Arch Gerontol Geriatr 49:e101-4. 2009..DLB subjects have a different neuropsychological profile, more psychiatric symptoms and more serious functional deficits than AD subjects in the early cognitive decline, furthermore DLB caregivers are more stressed than AD caregivers...
- Frontal and associative visual areas related to visual hallucinations in dementia with Lewy bodies and Parkinson's disease with dementiaCristina Sanchez-Castaneda
Dementia Unit, Department of Neurology, Bellvitge University Hospital, Barcelona, Spain
Mov Disord 25:615-22. 2010..The patterns of structural and functional correlations were different in both pathologies...
- Usefulness of a blood flow analyzing program 3DSRT to detect occipital hypoperfusion in dementia with Lewy bodiesMasaru Tateno
Department of Neuropsychiatry, Sapporo Medical University, Sapporo, Japan
Prog Neuropsychopharmacol Biol Psychiatry 32:1206-9. 2008..The quantitative analysis of brain perfusion SPECT by 3DSRT could be a useful supportive measurement in the diagnosis of DLB...
- Clinical and neuropathological correlates of apolipoprotein E genotype in dementia with Lewy bodiesAndrew B Singleton
Medical Research Council University of Newcastle upon Tyne, Centre Development in Clinical Brain Ageing, MRC Building, Newcastle upon Tyne, UK
Dement Geriatr Cogn Disord 14:167-75. 2002..This study demonstrates that DLB shares the APO epsilon4 allele with AD as a common risk factor, but that there are differences in the way the epsilon4 allele affects the phenotypic expression of disease...
- Exploring the Role of the Brain Epigenome: Cognitive Decline and Life ExperiencesDavid Alan Bennett; Fiscal Year: 2013..e., Alzheimer's disease, cerebrovascular disease, and Lewy body disease), these conditions only account for about 20% of the variance of cognition in older persons...
- Radiolabled MAO-B Substrates for ImagingMichael R Kilbourn; Fiscal Year: 2012..epilepsy), differentiation of related diseases (Alzheimer's versus frontal-temporal dementia (FTD) or Lewy Body disease), and evaluation of new therapeutic treatments, and thus could significantly assist in the diagnosis and ..
- Cognitive Decline and Dementia: Life Experiences and the Brain Histone EpigenomeDavid A Bennett; Fiscal Year: 2010..in old age often results from one or more of three common brain diseases, AD, cerebrovascular disease, and Lewy body disease, these conditions only account for about 20% of the variance of cognition in older persons...
- Role of impaired cognitive states &risk factors in conversion to mixed dementiasLei Yu; Fiscal Year: 2013..Alzheimer's disease (AD) from other prevalent brain diseases that include vascular dementia (VaD) and Lewy body disease (LBD)...
- A Novel Ubiquitin-Dependent Pathogenic Pathway in Spongiform NeurodegenerationLih Shen Chin; Fiscal Year: 2013..this pathology is also present in the brains of patients suffering from Alzheimer's disease, diffuse Lewy body disease, and acquired immune deficiency syndrome (AIDS)...
- Development of a Plasma Biomarker of Alzheimer's DiseaseMARK ANTHONY LOVELL; Fiscal Year: 2012..analyzed from subjects with non-AD neurodegenerative diseases including frontotemporal dementia and diffuse Lewy body disease. In addition, we will test whether pre-conversion PDS/TTR concentrations alone, or in combination with A[..
- Progranulin interaction with Sortilin in FrontoTemporal DementiaStephen M Strittmatter; Fiscal Year: 2013..dementia (FTD) is the third most common cause of neurodegenerative dementia, after AD and Diffuse Lewy Body Disease. The clinical features of FTD include memory deficits, behavioral abnormalities, personality changes and ..
- Therapeutic Targeting of Abnormal Conformation in Neurodegenerative DiseaseThomas M Wisniewski; Fiscal Year: 2013..AD) is the most common of the neurodegenerative protein conformational disorders, which include diffuse Lewy body disease (DLBD), Parkinson's disease (PD), prion diseases, and frontotemporal lobar degeneration (FTLD)...
- Molecular Genetic Analysis of Lysosomal Storage Disorder Genes in PDLorraine N Clark; Fiscal Year: 2011..R21, NS050487, we have shown that mutations in the glucocerebrosidase gene are risk factors for PD and Lewy body disease. In the current application we propose to continue our studies on the GBA gene and will examine three ..
- a-synuclein clearance strategies for the treatment of Lewy body diseaseEliezer Masliah; Fiscal Year: 2013b>Lewy body disease (LBD) is a group of disorders characterized by alpha-synuclein (alpha-syn) accumulation and parkinsonism...
- Pathological basis of MRS and DTI changes in neurodegenerative dementiaKejal Kantarci; Fiscal Year: 2013..cognitive decline, mild cognitive impairment (MCI) and dementia are Alzheimer's disease (AD) and Lewy body disease (LBD) pathologies...
- National Brain and Tissue Resource for Parkinson's Disease and Related DisordersThomas G Beach; Fiscal Year: 2013..by applicant): Parkinson's disease (PD) and related Lewy body disorders (LBD), including incidental Lewy body disease (ILDB), Alzheimer's disease with Lewy bodies (ADLB) and dementia with Lewy bodies (DLB) may affect up ..
- Varian 4 Tesla MRI/MRS for Neuro-degenerative DiseasesMichael Weiner; Fiscal Year: 2002..have funded projects on normal aging, Alzheimer's disease, frontotemporal dementia, vascular dementia, Lewy Body disease, epilepsy, Parkinson's disease, amyotrophic lateral sclerosis, post traumatic stress disorder, schizophrenia,..
- EMISSION COMPUTED TOMOGRAPHY OF LOCAL CEREBRAL FUNCTIONDavid Kuhl; Fiscal Year: 2001..have the premortem clinical criteria and neuro-psychological profile which have been attributed to Diffuse Lewy Body Disease (DLBD)...
- Alpha-Synuclein: A Drug Target for Parkinson's DiseaseMichael Lebowitz; Fiscal Year: 2001..that act as a-synuclein oligomerization inhibitors, and begin pre-clinical testing of both the small molecule and peptide-based drug candidates in animal models of Lewy body disease. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE
- DEMENTIA WITH PARKINSONISM: WHAT ARE WE DIAGNOSING?Carol Lippa; Fiscal Year: 1999..The more recently recognized Lewy body disease (LBD), as a presumptive third entity, may also produce a clinical and pathological syndrome that can ..
- NEUROPSYCHOLOGY OF DEMENTIA WITH LEWY BODIESTANIS FERMAN; Fiscal Year: 2009..This has implications for symptom management, development of treatment options and for providing education and support to DLB patients and their caregivers. ..
- Dementia of Parkinson Type: Clinicopathologic PhenotypeJames Galvin; Fiscal Year: 2004..At the completion of the award period, candidate plans to develop an independent R01 project derived from the data generated by the experiments described in this proposal. ..
- BASIS OF SYNAPTIC PATHOLOGY IN ALZHEIMERS DISEASEEliezer Masliah; Fiscal Year: 2001..These studies will help to better understand the mechanisms of synaptic pathology in AD and to develop potential neuroprotective agents that will operate by enhancing the GT activity. ..
- Visual Cognition in Dementia with Lewy BodiesJoanne M Hamilton; Fiscal Year: 2010....
- Study on Thalidomide as BACE1 inhibitor in Alzhiemer's diseaseMarwan N Sabbagh; Fiscal Year: 2010..We propose that Thalidomide may represent a BACE1 inhibitor. ..
- AMYLOIDOGENIC EFFECTS OF CHOLINERGIC DENERVATIONThomas Beach; Fiscal Year: 2002..This could lead to impaired cerebral vasoregulation and increased susceptibility to ischemia, further compromising cortical function in AD. ..
- B-Synuclein as a Treatment for Lewy Body DiseaseEliezer Masliah; Fiscal Year: 2005The new title of this revised application: "beta- synuclein as a treatment for Lewy body disease" reflects the modified and sharper focus on our scientific approach in response to the reviewers' major concern that synuclein might be more ..
- Implementation of [18F] FEOBV for VAChT Imaging with PETRobert Koeppe; Fiscal Year: 2004..g. AD). R33 (Year 5): Conclude clinical evaluations in normal control and patient groups. ..
- Pioglitazone in Alzheimer's Disease ProgressionDavid Geldmacher; Fiscal Year: 2003..Comparison of mean differences (using last observation carried forward imputation techniques) and survival analyses will be employed to assess for group differences in clinical measures AD of progression. ..
- Sleep, Circadian Rhythms and Dementing IllnessesDavid Harper; Fiscal Year: 2007..in the etiology of sleep-wake disturbance in Alzheimer's disease, frontotemporal degeneration, and Lewy body disease. In addition, we have found abnormalities in SCN cellular populations in men linked with specific circadian ..
- Risk Factors and the Neurobiologic Substrate of FrailtyAron Buchman; Fiscal Year: 2009..abstract_text> ..
- DEPRESSION DIAGNOSIS AND TREATMENT IN PARKINSON DISEASEDaniel Weintraub; Fiscal Year: 2008..abstract_text> ..
- Biomarkers in Aging, MCI and Alzheimer's DiseaseDouglas Galasko; Fiscal Year: 2007..Banked CSF and plasma will be available for further research into novel biomarkers, including broad-based proteomic studies. ..
- AGE RELATED NEURODEGENERATIVE DISEASES IN MICRONESIADouglas Galasko; Fiscal Year: 2006..Subproject by Lee: 'PHF-tau in neurodegenerative diseases of Guam' will assess oxidative markers related to brain lesions in ALS, PDC and dementia. ..
- Conference on the Diagnosis of Multiple System AtrophySid Gilman; Fiscal Year: 2006..This conference will assist with early diagnosis by developing new guidelines for diagnosis using newly available imaging and neuropathological criteria. [unreadable] [unreadable] [unreadable]..
- Sleep/Wake Contiuum in Lewy Body DiseaseDonald L Bliwise; Fiscal Year: 2010..The proposed work will also provide important clinical insights into disease correlates and disease course across the broad spectrum of Parkinsonism. ..
- Genetic Analysis of Tau H1 in ParkinsonismMatthew Farrer; Fiscal Year: 2006..abstract_text> ..
- In vivo mapping of gray matter loss in preclinical ADSatoshi Minoshima; Fiscal Year: 2007..If very early involvement of the posterior cingulate and association cortices are found consistently, these findings will provide better markers for early detection of the disease and monitoring of disease progression. ..
- Sleep Disordered Breathing, APOE and Lipid MetabolismEmmanuel Mignot; Fiscal Year: 2005..With lipid metabolism being critical to cardiovascular risk, this application will also trigger further studies focusing on cardiovascular impact with adequate control of SDB. ..
- dementias of the Alzheimer's TypeGeorge Martin; Fiscal Year: 2005..abstract_text> ..
- LIPID PEROXIDATION, TOXICANTS, AND MITOCHONDRIAMATTHEW PICKLO; Fiscal Year: 2003..With this knowledge, novel therapeutic interventions or preventative strategies may be designed for these diseases. ..
- SUNDOWN SYNDROME IN A SKILLED NURSING FACILITYDonald Bliwise; Fiscal Year: 2002..These results will provide information on the mechanistic basis for sundowning in aged patients with dementing disorders. ..
- Mechanisms of amyloid-beta clearance.Brian Bacskai; Fiscal Year: 2006..The results will strongly impact the development of treatments aimed at removing senile plaques and the associated neurological damage in Alzheimer's disease. ..
- SLEEP HOMEOSTASIS AND STIMULANT DRUGS OF ABUSEEmmanuel Mignot; Fiscal Year: 2002....
- Circuitry of Midbrain Dopamine in Sleep & WakeDavid Rye; Fiscal Year: 2005..g., schizophrenia) and hypodopaminergic (e.g., PD and restless legs/periodic leg movements of sleep). ..
- Novel Pathways of HAARTmediated Neuronal Toxicity in the Central Nervous SystemKelly L Jordan Sciutto; Fiscal Year: 2010..abstract_text> ..
- White Matter Change and CNS Process in the ElderlyLisa Silbert; Fiscal Year: 2008..This application proposes a structured didactic mentorship program for the principal investigator, Dr. Lisa Silbert, to ensure her independence as a clinical investigator at the end of the 5-year award period. [unreadable] [unreadable]..
- Predictors of Alzheimers Disease in Mild Cognitive ImpairmentOscar Lopez; Fiscal Year: 2007..g., structural and perfusion MRI, plasma beta-amyloid) and the factors that modify the risk to express the clinical syndrome takes on an added importance. [unreadable] [unreadable] [unreadable] [unreadable]..
- Neuroprotective Effects of Enhanced Proteasome FunctionBARBARA SNIDER; Fiscal Year: 2006....
- Role of Hypocretin in Metabolic Effects of Sleep LossEmmanuel Mignot; Fiscal Year: 2008..These studies will be critical to extend our understanding of the association between chronic sleep loss, metabolism and body weight regulation. ..
- Predicting Driver Safety in Parkinson's DiseaseErgun Uc; Fiscal Year: 2007..Fair and accurate means of detecting unfit drivers with PD will help mitigate the tragedy of motor vehicle crashes caused by these impaired individuals. ..
- VAS-COG 2007Donald Royall; Fiscal Year: 2007..Many vascular cognitive disorders are preventable and potentially reversible. VAS-COG will provide a forum in which information on these important conditions can be exchanged and disseminated. [unreadable] [unreadable] [unreadable]..
- Anti-oxidant therapy in Alzheimer's diseaseBrian J Bacskai; Fiscal Year: 2010..abstract_text> ..
- PET IN HYPERKINETIC DISORDERS--A MULTICENTER STUDYDavid Eidelberg; Fiscal Year: 2001..This approach may have great utility in evaluating new interventions for the treatment of the hyperkinetic movement disorders. ..
- BRAINSTEM SUBSTRATES OF DOPAMINE MODULATED MOVEMENTSDavid Rye; Fiscal Year: 2002..g., OCD, ADD, Tourette's and schizophrenia, the results will also bear relevance to a wider spectrum of disease. ..
- Aging Brain: DTI, Subcortical Ischemia and BehavioralStephen Salloway; Fiscal Year: 2006..abstract_text> ..
- ROLE OF PROTEASOMAL DYSFUNCTION IN PARKINSON'S DISEASEKEVIN MCNAUGHT; Fiscal Year: 2008..These studies will test our hypothesis that inadequate proteasomal function underlies both vulnerability and degeneration of the SNc in sporadic Parkinson's disease. ..
- COMPARING THREE ELECTRODE PLACEMENTS TO OPTIMIZE ECTKeith Rasmussen; Fiscal Year: 2005..The results of this study will promote more effective and safer treatment of the most severely ill depressed patients. ..
- ENERGY METABOLISM, DOPAMINE NEURONS AND NEUROTOXICITYGail Zeevalk; Fiscal Year: 2008..The studies will have relevance to neurodegenerative conditions or pathophysiological situations in which metabolism is compromised. ..
- Seeking the Biomarkers of Aging and Diseases of Aging conferenceGeorge Martin; Fiscal Year: 2007..unreadable] [unreadable] [unreadable]..
- Second International Brainstorming Meeting on Parkinson Disease: NosologyIrene Litvan; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- Frontotemporal degeneration: a basis for clinical trialsDavid Knopman; Fiscal Year: 2006..abstract_text> ..
- PANDAS and Strep Infection: Are they Linked?Roger Kurlan; Fiscal Year: 2004..Disproving the PANDAS hypothesis would prevent the use of expensive and potentially dangerous therapies (e.g., plasma exchange, immune globulin, antibiotics) that have been proposed for PANDAS patients. ..